Cytrx Corporation

Other

Emory University

Rush-presbyterian-st. Luke's Medical Center

Artelo Biosciences, Inc.

Liferaft Biosciences, Inc.

Mast Therapeutics, Inc.

Aires Pharmaceuticals, Inc.

Rush Prebyterian-st. Luke Medical Center

R Martin Emanuele

Mannarsamy Balasubramanian

Robert L Hunter

Paula H Culbreth

Mark Joseph Newman

Hameedsulthan S Allaudeen

Carlos A Rivera-Marrero

Charles William Todd

Robert Newton Brey, Iii

John S Coon

Himanshu Shah

Stewart V Smith

Patricia Andres

Mark Andres

Konstantin G Kousoulas

Tanise Shattock-Gordon

Tabitha Williford

Robert Hunt Carpenter

Santosh Vetticaden

Daiva K Tautvydas

Patrick Keran

StewartV Smith

Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4'-dipyridyl are also disclosed herein.

Solid forms of cannabidiol and uses thereof

Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Poloxamer composition free of long circulating material and methods for production and uses thereof

Provided methods of administering poloxamer 188 for treating heart failure by only a single short relatively high dose infusion, or by regimen that includes the single infusion followed by additional infusions at intervals of 1-4 weeks.

Poloxamer therapy for heart failure

The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula:HO(CHO)(CHO)(CHO)Hwherein a is an integer such that the hydrophobe represented by (CHO) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.

Therapeutic delivery compositions and methods of use thereof

The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymers compositions and compounds. The compositions comprise block copolymers that are useful in gene therapy methods.

Adjuvants and copolymer compositions

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula:wherein 'b' represents a number such that the molecular weight of the hydrophobe (CHO)is between approximately 750 and 20,000 Daltons and 'a' represents a number such that the percentage of hydrophile (CHO)is between approximately 1% and 90% of the weight of the block copolymer.

The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.

Vaccine adjuvant and vaccine method

The present invention comprises preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

Polyoxypropylene/polyoxyethylene copolmers with improved biological activity

Vaccine adjuvant and vaccine

Growing community of inventors

Alpharetta, GA, United States of America

R Martin Emanuele